Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Oct 29, 11:38 AMBaxter raises 2026 guidance after Q3 beat as turnaround gains traction despite injectables, 2027 headwinds
Index
S&P 500
Market Cap
12.33B
Enterprise Value
18.34B
Income
-705.00M
Sales
11.61B
Book/sh
12.57
Cash/sh
3.82
Employees
37500
IPO
May 16, 1961
P/E
-
Forward P/E
11.70
PEG
-
P/S
1.06
P/B
1.90
P/C
6.24
P/FCF
10.84
EV/EBITDA
11.17
EV/Sales
1.58
Quick Ratio
1.19
Current Ratio
1.79
Debt/Eq
1.23
LT Debt/Eq
1.10
Option/Short
Yes / Yes
EPS (ttm)
-1.38
EPS next Y
2.04
EPS next Q
0.60
EPS this Y
-5.30%
EPS next Y
-2.66%
EPS next 5Y
-0.64%
EPS past 3/5Y
24.78% -
Sales past 3/5Y
-8.14% -0.75%
EPS Y/Y TTM
-164.67%
Sales Y/Y TTM
5.33%
EPS Q/Q
3130.86%
Sales Q/Q
4.97%
Insider Own
0.64%
Insider Trans
0.00%
Inst Own
108.88%
Inst Trans
3.30%
ROA
-3.06%
ROE
-9.01%
ROIC
-5.16%
Gross Margin
31.92%
Oper. Margin
5.92%
Profit Margin
-6.07%
SMA20
-3.37%
SMA50
-2.85%
SMA200
11.60%
Trades
Shs Outstand
517.35M
Shs Float
514.04M
52W High
30.00 -20.56%
52W Low
15.73 51.51%
Volatility
4.99% 3.46%
ATR (14)
0.92
RSI (14)
45.03
Beta
0.67
Rel Volume
0.83
Avg Volume
6.64M
Volume
4,237,066
Perf Week
-5.76%
Perf Month
1.46%
Perf Quarter
-15.94%
Perf Half Y
43.39%
Perf YTD
24.71%
Perf Year
29.03%
Perf 3Y
-30.42%
Perf 5Y
-70.32%
Perf 10Y
-49.01%
Prev Close
23.00
Price
23.83
Change %
3.62%
Consensus
Hold
Avg. Price Target
$25.91
Implied Upside
+8.7%
Analysts13incl. previous ratings
Rating Distribution0 Buy · 11 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2026Initiated
WWolfe Research
Peer Perform
Oct 07, 2026Initiated
BCS logoBBarclays
Underweight$20-16.1%
Jul 31, 2026Upgrade
C logoCCitigroup
Sell → Neutral$28+17.5%
May 28, 2026Downgrade
C logoCCitigroup
Neutral → Sell$17-28.7%
Oct 31, 2025Downgrade
AArgus
Buy → Hold
Aug 04, 2025Downgrade
SF logoSStifel
Buy → Hold$25+4.9%
Aug 01, 2025Downgrade
GS logoGGoldman
Buy → Neutral$25+4.9%
Feb 26, 2025Resumed
GS logoGGoldman
Buy$42+76.2%
Feb 24, 2025Upgrade
AArgus
Hold → Buy
Feb 20, 2025Resumed
BCS logoBBarclays
Overweight$39+63.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STEPHEN N. OESTERLE REV TRUSTFormer AffiliateMay 18 '26Proposed Sale17.7536,347645,236May 18 04:57 PM
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment sells connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment focuses on the sales of specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
CEOMr. Andrew P. Hider
Executive VP & General CounselMr. David S. Rosenbloom
Group President of Infusion Therapies & PlatformsMs. Maria Soriano
Executive VP & CFOMr. John Terence Rogers
Interim Chief Accounting Officer & ControllerMr. Bernie Heine